Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials.

ABSTRACT:

Aim of the review

To assess the risk of hypovolemia for sodium-glucose cotransporter-2 (SGLT2) inhibitors treatment.

Method

A systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 October 2022, Data for study characteristics and outcomes of interest were extracted from each eligible study. Risk ratios (RRs) with a 95% confidence interval (CI) for hypovolemia were calculated using a random-effect model.

Results

A total of 57 studies (n = 68,622) were included in our meta-analysis, with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02-1.22). It is evid

SUBMITTER: Rong X 

PROVIDER: S-EPMC9701837 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature